Megalotect

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect, is an immunoglobulin presented as a sterile intravenous solution for intravenous use. It provides passive immunity to prevent cytomegalovirus infection in transplant recipients and to treat active CMV disease in immunocompromised patients.

GNH USA supplies Megalotect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Megalotect is an immunoglobulin that targets the cytomegalovirus family, providing passive immunity for both prevention and treatment. - Prevention of cytomegalovirus infection in transplant recipients: supplies antibodies to reduce the risk of primary CMV infection after transplantation. - Treatment of cytomegalovirus disease: delivers neutralising antibodies that assist viral clearance in patients with active CMV infection. - Prophylaxis in high‑risk immunocompromised patients: administered to lower the incidence of CMV reactivation in vulnerable individuals.

Megalotect may be associated with infusion‑related and immune‑mediated reactions.

Common Side Effects: - Fever - Chills - Headache - Nausea - Fatigue - Mild infusion‑related reactions (e.g., erythema, itching)

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Hemolysis - Renal dysfunction or acute kidney injury - Thromboembolic events - Aseptic meningitis - Severe hypotension during infusion

Megalotect requires careful patient assessment and monitoring. - Assess CMV serostatus: determine baseline immunity before administration. - Monitor for infusion reactions: observe vital signs during and after infusion. - Evaluate renal function: adjust use in patients with impaired kidneys. - Avoid in individuals with known IgA deficiency and anti‑IgA antibodies: risk of severe allergic response. - Use with caution in pregnancy or breastfeeding: safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Megalotect can interact with other therapies that affect immunity or coagulation.

Major Interactions (Avoid): - Concomitant use with other immunoglobulin products may cause volume overload. - Co‑administration with live vaccines may reduce vaccine efficacy. - Use with anticoagulants may increase bleeding risk. - Concurrent nephrotoxic drugs may exacerbate renal impairment. - Combination with monoclonal antibodies targeting immune cells may alter therapeutic response.

Moderate Interactions (Monitor Closely): - Corticosteroids may mask infusion‑related symptoms. - Antiviral agents such as ganciclovir may require dose adjustment. - Diuretics can affect fluid balance during infusion. - Other blood products may increase volume load. - Inactivated vaccines may have altered immunogenicity when given with Megalotect.